ArticleThe Journal of biological chemistry2009
Regulated proteolysis of nonmuscle myosin IIA stimulates osteoclast fusion.
Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Moesin controls cell-cell fusion and osteoclast function.The Journal of cell biology · 2025Article
- Glycobiology in osteoclast differentiation and function.Bone research · 2023Review
- Crosstalk between dihydroceramides produced by Porphyromonas gingivalis and host lysosomal cathepsin B in the promotion of osteoclastogenesis.Journal of cellular and molecular medicine · 2022Article
- Cellular and molecular actors of myeloid cell fusion: podosomes and tunneling nanotubes call the tune.Cellular and molecular life sciences : CMLS · 2021Review
- Comparative antler proteome of sika deer from different developmental stages.Scientific reports · 2021Article
- Osteoclast Multinucleation: Review of Current Literature.International journal of molecular sciences · 2020Review
- Genetic mapping of distal femoral, stifle, and tibial radiographic morphology in dogs with cranial cruciate ligament disease.PloS one · 2019Article
- Myosins in Osteoclast Formation and Function.Biomolecules · 2018Review
- Regulation of Osteoclast Differentiation by Myosin X.Scientific reports · 2017Article
- Symmetrical retrograde actin flow in the actin fusion structure is involved in osteoclast fusion.Biology open · 2017Article
- Phosphoglycerol dihydroceramide, a distinctive ceramide produced by Porphyromonas gingivalis, promotes RANKL-induced osteoclastogenesis by acting on non-muscle myosin II-A (Myh9), an osteoclast cell fusion regulatory factor.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2017Article
- Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.Cancer research · 2016Article
- The RhoGAP activity of myosin IXB is critical for osteoclast podosome patterning, motility, and resorptive capacity.PloS one · 2014Article
- Genetic basis of cell-cell fusion mechanisms.Trends in genetics : TIG · 2013Review
- Paxillin contracts the osteoclast cytoskeleton.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012Article
- An essential role for the association of CD47 to SHPS-1 in skeletal remodeling.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011Article
- Quantitative proteomic analysis of dexamethasone-induced effects on osteoblast differentiation, proliferation, and apoptosis in MC3T3-E1 cells using SILAC.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2011Article
- Feeding blueberry diets in early life prevent senescence of osteoblasts and bone loss in ovariectomized adult female rats.PloS one · 2011Article
- c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation.The Journal of biological chemistry · 2010Article
- Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.British journal of cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The nonmuscle myosin IIA heavy chain (Myh9) is strongly associated with adhesion structures of osteoclasts. In this study, we demonstrate that during osteoclastogenesis, myosin IIA heavy chain levels are temporarily suppressed, an event that stimulates the onset of cell fusion. This suppression is not mediated by changes in mRNA or translational levels but instead is due to a temporary increase in the rate of myosin IIA degradation. Intracellular activity of cathepsin B is significantly enhanced at the onset of osteoclast precursor fusion, and specific inhibition of its activity prevents myosin IIA degradation. Further, treatment of normal cells with cathepsin B inhibitors during the differentiation process reduces cell fusion and bone resorption capacity, whereas overexpression of cathepsin B enhances fusion. Ongoing suppression of the myosin IIA heavy chain via RNA interference results in formation of large osteoclasts with significantly increased numbers of nuclei, whereas overexpression of myosin IIA results in less osteoclast fusion. Increased multinucleation caused by myosin IIA suppression does not require RANKL. Further, knockdown of myosin IIA enhances cell spreading and lessens motility. These data taken together strongly suggest that base-line expression of nonmuscle myosin IIA inhibits osteoclast precursor fusion and that a temporary, cathepsin B-mediated decrease in myosin IIA levels triggers precursor fusion during osteoclastogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.